drug
Carboplatin Pfizer
Marketedupdated 3mo agoby $PFE PFIZER INC
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- drugcarboplatin6 co-mentions · 6 sources
- tagOncology6 co-mentions · 2 sources
- tagBreast Cancer4 co-mentions · 1 sources
- tagDrug Shortage3 co-mentions · 3 sources
- tagPulmonology2 co-mentions · 1 sources
- tagNSCLC2 co-mentions · 1 sources
- tagApproval2 co-mentions · 1 sources
- companyAccord Healthcare Inc1 co-mentions · 1 sources
all catalysts(2)
Trials studying Carboplatin Pfizer
- phase3DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
- phase3A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- phase3Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
- phase1A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
- phase3A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
- phase3A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
- phase3Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)
- phase3Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
Patent cliff
source: FDA Orange Bookfirst barrier falls
Apr 1, 2045
~18.6 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (3)
- Apr 1, 2045formulationUS 12427104
- Apr 1, 2045formulationUS 12427104
- Apr 1, 2045formulationUS 12427104
News(4)
- Ultra-low doses could bring costly cancer treatments to more patients in poorer countriesLow-dose, low-cost immunotherapies may help patients in poorer countries access high-tech cancer treatments.stat · 2mo ago
- Immunotherapy Advances in Upfront SCAC Expose Need for Better Second-Line StrategiesAparna R. Parikh, MD, emphasizes the feasibility of immunotherapy trials in SCAC and the need for better treatment options in the second line and beyond.onclive · 3mo ago
- Poll Results Highlight Breast Cancer Abstracts of Interest at ASCO 2026Readers share their opinions on some of the most talked-about breast cancer abstracts they’re looking forward to seeing at ASCO 2026.onclive · 3mo ago
- ASCO 2026 HR+ and HER2+ Breast Cancer Preview: Read up on the Insights to Know Before You GoBreast cancer experts spotlight the abstracts they’re most excited to see at the 2026 ASCO Annual Meeting.onclive · 3mo ago
Data sources
last refreshed 6m ago
Found something off?
comments(0)
5-min edit window · permanent after that